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Abstract
Increased oxidative stress in a failing heart may contribute to the pathogenesis of heart failure (HF). The aim of this study
was to identify the oxidised proteins in the myocardium of HF patients and analyse the consequences of oxidation on
protein function. The carbonylated proteins in left ventricular tissue from failing (n = 14) and non-failing human hearts
(n = 13) were measured by immunoassay and identified by proteomics. HL-1 cardiomyocytes were incubated in the
presence of stimuli relevant for HF in order to assess the generation of reactive oxygen species (ROS), the induction of
protein carbonylation, and its consequences on protein function. The levels of carbonylated proteins were significantly
higher in the HF patients than in the controls (p,0.01). We identified two proteins that mainly underwent carbonylation: M-
type creatine kinase (M-CK), whose activity is impaired, and, to a lesser extent, a-cardiac actin. Exposure of cardiomyocytes
to angiotensin II and norepinephrine led to ROS generation and M-CK carbonylation with loss of its enzymatic activity. Our
findings indicate that protein carbonylation is increased in the myocardium during HF and that these oxidative changes
may help to explain the decreased CK activity and consequent defects in energy metabolism observed in HF.
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Introduction
There is experimental evidence showing increased oxidative
stress in a failing heart and that this contributes to the pathogenesis
of the myocardial remodelling that leads to heart failure (HF) [1].
Patients with chronic HF have high levels of oxidative stress
markers, which have been related to myocardial dysfunction and
the overall severity of HF [1]. Increased levels of lipid peroxidation
markers and broached antioxidant reserves have both been
reported in humans with HF [2,3]: in particular, the pericardial
levels of 8-iso-prostaglandin F2alpha increase with the functional
severity of HF and are associated with left ventricular (LV) dilation
[2], and the cardiac tissue levels of 4-hydroxy-2-nonenal correlate
with systolic dysfunction [4]. Furthermore, Dhalla et al. have
reported that oxidative stress in the myocardium of guinea pigs
increases during the transition from compensatory hypertrophy to
HF subsequent to chronic pressure overload [5].
These findings are not surprising because it is known that
oxidative damage can be caused by a number of factors associated
with HF, including high plasma catecholamine levels, increased
cardiac sympathetic tone, microvascular reperfusion injury,
cytokine stimulation, and mitochondrial deoxyribonucleic acid
mutations. Reactive oxygen species (ROS) are produced in the
failing myocardium by different sources, and cause hypertrophy,
injury, apoptosis, and necrosis in cardiomyocytes [6–12].
ROS can modify various biological molecules, such as
carbohydrates, lipids, nucleic acid and proteins [13]. Proteins
are the main targets because they are abundant in biological
systems and primarily responsible for the processes of most cell
functions; it has also been estimated that they can scavenge the
majority (50–75%) of ROS [14]. Most protein modifications are
irreparable, and oxidative changes in protein structure can have a
wide range of downstream functional consequences as they may
inhibit enzymatic or binding activities, increase susceptibility to
aggregation and proteolysis, increase or decrease cell uptake, and
alter immunogenicity [14].
The most widely studied oxidative stress-induced protein
modification is the formation of carbonyl groups on amino acid
residues [14]. The amount of carbonyls is considered a marker of
oxidative stress, and is used to quantify the level of oxidative
damage in polypeptide chains [14]. Moreover, analysing protein
carbonyl groups may have some advantages over other methods:
their formation is a common product of protein oxidative
reactions, and they are produced early, remain relatively stable,
and are induced by almost all types of ROS [15].
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It is now known that protein oxidation plays an essential role in
the pathogenesis of a large number of degenerative diseases [16].
However, a complete analysis of protein carbonylation in the
myocardium of HF patients is still lacking.
Aim of this study is to gain a deeper insight in the effects of ROS
on protein carbonylation in the human failing heart, and, in
particular: a) to analyse the presence of carbonylated proteins in
the myocardium of HF patients; b) to identify the targets of
carbonylation using a proteomic approach; and c) to identify the
molecules responsible for protein oxidation in in vitro cultured
cardiomyocytes.
Materials and Methods
Unless otherwise specified, all reagents and chemicals were
purchased from Sigma-Aldrich, Milan, Italy.
Ethic Statement
The study protocol was approved by the Ethics Committees of
Monzino Cardiologic Center and Niguarda Hospital, and was
conducted in accordance with the principles laid down in the
Declaration of Helsinki.
Subjects and Heart Tissue Samples
Non-failing left ventricular apical tissue was harvested from 13
donor hearts excluded from transplantation for technical reasons
(mean ejection fraction: 6564%) at the Homograft Bank of
Monzino Cardiologic Center (Milan, Italy) and immediately
frozen at 280uC. The mean age of the donors was 4662.2 years;
seven were male.
Non necrotic tissue from the apex of 14 failing hearts was
obtained from patients undergoing cardiac transplantation at
Niguarda Hospital, all of whom gave their written informed
consent. The cause of heart failure was idiopathic dilated
cardiomyopathy (n = 7), and ischemic cardiomyopathy (n = 7).
The mean age of the patients was 4662.2 years; six were male. All
of the patients had an ejection fraction of,20%, but none of them
was on the urgent heart transplant list. Moreover, only two had
been treated with a long term left ventricular assist device or had
received chronic intravenous inotropic support during the seven
days preceding transplantation. Heart failure therapy was
optimised in all cases and included angiotensin-converting enzyme
inhibitors (77%), b-blockers (70%), diuretics (85%), antiarrhythmic
drugs (15%), antiplatelets (62%), anticoagulant drugs (38%). The
comorbidities were hypertension (46% of the patients) and
diabetes (23%).
Protein Extraction from Heart Tissue
The heart tissue specimens were ground to a powder under
liquid nitrogen using a mortar and pestle, resuspended in
20 mmol/L HEPES, 20 mmol/L NaCl, 5 mmol/L EDTA, 1%
w/v CHAPS with protease inhibitors (Sigma-Aldrich) (1 g of tissue
in 7 mL), homogenised at setting 5 of a Polytron homogenizer
(three 10 s bursts), sonicated using a Branson Sonifier 250 (three
times for 20 s each), and centrifuged at 130006g for 10 min at
4uC. The supernatants were treated with protein-L-agarose for
45 min (20 microlitres per 1 mL) in order to eliminate contam-
inating immunoglobulins. After centrifugation, the supernatants
were recovered and protein concentration was measured using
Bradford’s assay [17].
Quantification of Protein Carbonyl Groups
Cardiac protein carbonyls were measured using a Zentech PC
test ELISA (Biocell, Auckland, New Zealand). Briefly, heart tissue
protein lysate prepared as described above was reacted with 2,4-
dinitrophenylhydrazine (DNPH) in order to convert the protein
carbonyl groups to the corresponding 2,4-dinitrophenylhydra-
zones (DNP), which can be detected by means of an anti-DNP
antibody. Absorbances were read using a 450 nm filter. The
standard curve of oxidised albumin and the samples were assayed
in triplicate; the intra- and inter-assay coefficients of variation were
respectively less than 2.1% and 3.2%.
Sample Preparation and 2-dimensional Electrophoresis
for the Detection of Protein Carbonyls
The cardiac proteins were diluted in a buffer yielding final
concentrations of 8 mol/L urea, 2 mol/L thiourea, 4% w/v
CHAPS, 2% v/v carrier ampholytes, pH 3–10, 20 mmol/L Tris,
55 mmol/L DTT, and bromophenol blue. Two-dimensional
electrophoresis (2-DE) was carried out in accordance with the
manufacturer’s protocol (Protean IEF cell, Biorad, Milan, Italy),
with 70 mm IPG ready strips, pH 3–10 non-linear gradient
(Biorad, Milan, Italy), as described in the Methods S1. All of the
analyses were made in duplicate: one gel was stained with
Coomassie Colloidal Blue G250 for total protein analysis, and the
other was electroblotted to a polyvinylidene fluoride (PVDF)
membrane for DNP immunostaining to evaluate the carbonylated
proteins as previously described [18]. The procedure was
performed in triplicate for each sample in order to evaluate gel
reproducibility and improve the reliability of the estimates of
qualitative and quantitative changes in protein expression.
All of the images were scanned using a GS-800 densitometer
(Biorad, Milan, Italy) before being analysed by means of
Progenesis SameSpot software (Nonlinear Dynamics, Newcastle
upon Tyne, UK).
Progenesis SameSpot software v 2.1 was used for gel alignment,
spot detection, spot quantification, and normalisation for total spot
volume in each gel, and the data were statistically analysed using
the incorporated statistical package. Oxidation index was then
calculated as the ratio between spot immunointensity divided by
intensity of Colloidal Blue protein staining. The cut-off level for a
differentially expressed oxidized protein was defined as at least a
1.5 fold increase or decrease in protein oxidation index.
Statistically significant between-group differences for each
protein were computed using the non-parametric Wilcoxon
Mann-Whitney test, and a p value of ,0.05 was considered
statistically significant. Proteins with altered immunoreactivity
were identified by mass spectrometry (MS) after excision of the
matching spot on the superimposed gel stained with Coomassie
Blue.
Mass Spectrometry Analysis
The selected proteins were in-gel reduced, alkylated, digested
with trypsin as previously described [19] and the samples were
analysed by liquid chromatography-mass spectrometry (LC-MS/
MS), with the spectra being recorded by a hybrid quadrupole
orthogonal acceleration time-of-flight Q-Tof mass spectrometer
with an electrospray ionization (ESI) source (Synapt-MS, Waters
corporation, Manchester, UK), connected to a Nano-Acquity
UPLC system. Further details are available in the Methods S1.
Cell Culture Experiments
The HL-1 cardiomyocytes were a kind gift of Professor W.C.
Claycomb, LSU Health Sciences Center, New Orleans, LA, USA
[20] and were cultured in complete Claycomb Medium supple-
mented with 10% fetal calf serum (FCS) (JRH Biosciences,
Lenexa, KS, USA) and 100 mmol/L norepinephrine (Sigma-
Protein Oxidation in Heart Failure
PLoS ONE | www.plosone.org 2 May 2012 | Volume 7 | Issue 5 | e35841
Aldrich, Milan, Italy), following Professor Claycomb’s instructions.
The cells were starved in a medium without serum and
norepinephrine for at least 24 h before incubation with the
various compounds (isoprotenerol, phenylephrine, norepineph-
rine, angiotensin II, endothelin-1, and TNFa) in the same
medium, to avoid the interference of serum factors which mask
the stimulatory effects of agonists (data not shown).
Formation of Intracellular Reactive Oxygen Species (ROS)
HL-1 cells cultured on 96-well plates were loaded with
10 mmol/L 29,79-dichlorofluorescein diacetate (DCFH-DA) for
1 h at 37uC and, after incubation, were washed in phosphate
buffered saline (PBS) and exposed to the various compounds or
vehicle for the indicated times. ROS production was measured on
the basis of the intensity of DCF emission at 535 nm (excitation
485 nm) in a Mithras LP940 fluorescence spectrometer (Berthold
Technologies Italia, Milan, Italy). The curve that remained after
subtracting the fluorescent signal of untreated cells from that of
treated cells was used to evaluate the stimuli-induced increase in
fluorescence; the results are expressed as the percentage increase
in fluorescence in comparison with the untreated cells.
Immunocytochemical Analysis of Protein Carbonyls
Protein carbonyls were detected using the protocol described by
Smith et al [21]. The treated cells were immediately fixed for 24 h
at 4uC using a solvent mixture (methanol/chloroform/acetic acid
60/30/10; v/v/v) to remove cellular lipids. After removing the
solvent mixture, the cells were incubated for 16 h at 4uC with
DNPH (300 mg DNPH per 100 mL 96% ethanol containing
1.5% pure sulfuric acid) in order to convert the protein carbonyl
groups to the corresponding 2,4-dinitrophenylhydrazones, which
can be detected using an anti-DNP antibody. The residual DNPH
was removed by first extensively washing the cells with PBS
containing 1% FCS (washing buffer) and then incubating them for
30 min at 4uC in washing buffer. The primary polyclonal anti-
DNP antibody (Sigma-Aldrich, Milan, Italy) was diluted 1:200 in
washing buffer for 1 h at 4uC, and after exhaustive washing, the
cells were treated with a secondary Alexa fluor 488-labeled anti-
rabbit antibody (Invitrogen, Milan, Italy) diluted 1:100 in washing
buffer for 1 h at 4uC. After removing the secondary antibody and
washing, the cells were microscopically examined.
CK Immunoprecipitation, Derivatisation by DNPH, SDS-
PAGE and Immunochemical Detection of Carbonylation
To analyse CK carbonylation in vitro, HL-1 cells were treated
with angiotensin II, phenylephrine or vehicle for 24 h, then
collected in ice-cold PBS and centrifuged at 7006g for 3 min. The
cell pellets were suspended in lysis buffer (50 mmol/L Tris,
150 mmol/l NaCl, 1% v/v Triton X-100, 1% w/v deoxycholate
and 0.1% w/v SDS, pH 8), supplemented with a cocktail of
protease inhibitors (Sigma-Aldrich), and lysed at 4uC for 30 min.
The cell lysates were sonicated three times for 10 s on ice and
centrifuged at 150006g for 15 min. After centrifugation, the
clarified supernatants were immunoprecipitated for 1 h at room
temperature with anti M-CK antibody (2 mg/mg protein, Santa
Cruz Biotechnology, Santa Cruz, CA, USA) cross-linked to the
uniformly sized super-paramagnetic nanoparticle Bio-Adembeads
Protein G (Ademtech, Pessac, France) as indicated in the
manufacturer’s protocol. To avoid the co-elution of immunoglob-
ulin, the antibody was cross-linked to the beads (2 mg per 20 mL of
beads) after treatment with 200 mmol/L triethanolamine and
20 mmol/L dimethyl pimelimidate dihydrochloride as the cross-
linker.
The Bio-Adembeads protein G cross-linked to the anti-CK
antibody were then incubated with the cell lysate in order to form
a magnetically labelled immune complex that can be easily
separated from the liquid by removing the supernatant with a
magnet. The immunoprecipitates were washed three times with
PBS before elution with 50 mmol/L glycine, 0.65% Tween,
pH 2.7.
The proteins were derivatised with 10 mmol/L DNPH (in 2 N
HCl) for 1 h at room temperature. The DNPH-derivatised
samples were neutralised with 10 mmol/L sodium phosphate
buffer, pH 7.45, containing 0.1% w/v SDS, 30% v/v glycerol and
5% v/v 2-b-mercaptoethanol, and the proteins were separated by
SDS-PAGE and blotted to PVDF membranes. Immunodetection
was performed using biotinylated anti-DNP antibody (Invitrogen,
Milan, Italy) and conjugated avidin-HRP (Biorad, Milan, Italy) or
anti M/B-CK antibody (Santa Cruz Biotechnology, Santa Cruz,
CA, USA). As a negative control, Bio-Adembeads Protein G was
incubated with cell lysate without antibodies.
Detection of S-nitrosylated CK
The occurrence of S-nitrosylated CK was assessed by means of
the biotin-switch assay [22] using the S-nitrosylation protein
detection kit (Cayman Chemical, Ann Arbor, MI, USA). This
method is aimed at converting nitrosylated cysteines into
biotinylated cysteines. Briefly, free thiols of proteins were blocked
with the thiol-specific agent methylmethanethiosulfonate. Then S-
nitrosothiols were selectively reduced by ascorbate to form thiols,
which were reacted with N-[6-(biotinamido)hexyl]-39-(29-pyridyl-
dithio)-propionamide, a sulfhydryl-specific biotinylating reagent.
After derivatization the biotinylated/S-nitrosylated CK was
immunoprecipitated as described above. Immunodetection was
performed using a biotin detection reagent and anti M/B-CK
antibody.
CK Activity
CK activity was measured in 10 mg of cell extract or cardiac
tissue homogenate using the EnzyChromTM Creatine Kinase
Assay Kit (BioAssay Systems’ QuantiChrom, Gentaur, Milan,
Italy), which is based on enzyme-coupled reactions in which
creatine phosphate and ADP are converted to creatine and ATP
by CK. The generated ATP is used to phosphorylate glucose by
hexokinase in order to generate glucose-6-phosphate, which is
then oxidised by NADP in the presence of glucose-6-phosphate
dehydrogenase. The produced NADPH, measured at 340 nm, is
proportionate to the CK activity in the sample, and the data are
expressed as percentage of CK activity in treated cells with respect
to control cells. Purified human M-CK was from Sigma-Aldrich.
Statistical Analysis
The numerical data are given as mean values6SD. The non-
parametric Wilcoxon Mann-Whitney test was used to compare the
controls and patients, with a p value of ,0.05 being considered
statistically significant. Statistically significant between-group
differences in the in vitro experiments were computed using
analysis of variance (ANOVA) followed by Tukey’s post hoc test in
order to allow both multiple group and individual group-to-group
comparisons; a p value of ,0.05 was considered statistically
significant. These statistical analyses were made using SPSS
software (v 13.0, SPSS, Chicago, IL, USA).
Results
Carbonylated protein levels measured by ELISA were signifi-
cantly higher in the hearts of the HF patients than in the control
Protein Oxidation in Heart Failure
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hearts (p,0.01, Wilcoxon Mann-Whitney analysis) (Fig. 1),
but the difference between the ischemic and idiopathic patients
was not significant (0.6060.32 nmoles/mg protein vs
0.8760.24 nmoles/mg protein; p = 0.34). The carbonylated pro-
teins were then identified by means of 2-DE combined with the
high specificity of immunoblotting after the DNPH derivatisation
of the carbonyl groups. Immunoblotting with anti-DNP antibody,
performed on 14 left ventricular tissue samples from HF patients
and 13 from healthy controls, showed that different isoforms of
two proteins were carbonylated to a greater extent in the
myocardium of the patients (Fig. 2 and Table S1). The
carbonylated protein spots were excised from the 2-DE gel,
digested with trypsin, and analysed by means of LC-MS/MS,
which identified them as a-cardiac actin (ACTC) and creatine
kinase M-type (M-CK), which is only detectable in its oxidised
form in failing hearts (Table S1). The analysis of CK activity
revealed that it was significantly reduced in the myocardium of HF
patients than in controls (88.9610.4 U/mg protein vs
17569.6 U/mg protein, p= 0.0001, respectively).
Considering that other forms of protein oxidation, such as those
induced by reactive nitrogen species, could have an impact on CK
activity we evaluated the occurrence of S-nitrosylation (i.e. the
covalent attachment of nitric oxide to cysteine thiol) in the
myocardium of controls and HF patients. S-nitrosylated proteins
were selectively biotinylated, CK was immunoprecipitated and the
S-nitrosylated form of CK was revealed with a biotin detection
reagent. This analysis revealed that there are no difference in
terms of S-nitrosylation of CK between controls and HF patients
(Fig. S1). Furthermore, the total profile of S-nitrosylated proteins
was very similar between control and HF patients (Fig. S1).
In order to identify the factors responsible for the increased
formation of carbonylated proteins, in vitro cultured HL-1
cardiomyocytes were exposed to the b1 and b2 agonist
isoprotenerol (0.1–1 mmol/L), the a1 agonist phenylephrine
(10–100 mmol/L), the a1, a2 and b1 agonist norepinephrine
(10–100 mmol/L), angiotensin II (10–100 nmol/L), endothelin-1
(10–100 nmol/L), and TNFa (1–10 ng/mL). Intracellular H2O2
formation measured on the basis of the intensity of DCF
emission was monitored for 1 h. All of the tested compounds
induced the rapid intracellular generation of H2O2, which
subsequently gradually decreased to baseline levels (Fig. 3).
We then looked for the presence of protein carbonyls in HL-1
cells exposed for different times to angiotensin II or phenylephrine,
the most potent H2O2 inductors under our experimental
conditions. As shown in Figure 4, carbonyls were clearly
detectable in the HL-1 cells incubated with both agents after
1 h, and remained detectable for up to 24 h.
In order to verify whether angiotensin II or phenylephrine
induced the carbonylation of M-CK protein, protein extracts from
control cells, and cells treated with angiotensin II or phenyleph-
rine, were immunoprecipitated with a specific mouse antibody
against M-CK cross-linked to Bio-Adembeads Protein G to avoid
the recognition of the heavy and light chain of immunoglobulins in
the primary antibody by the second antibody used for Western
blotting. After elution, the protein carbonyl groups were
derivatised with DNPH before being analysed by Western blotting
using an anti-protein-DNP antibody and a rabbit anti M-CK
antibody.
In comparison with the controls, M-CK protein carbonylation
was significantly increased by 2.560.9 fold in the angiotensin II-
treated cells (p,0.05) and by 1.860.7 fold in the phenylephrine-
treated cells (p,0.05) (Fig. 5).
As ROS can oxidatively modify proteins altering their biological
activity, [14,18] we investigated the relationship between the
oxidative modification and CK catalytic activity, which was
assessed in HL-1 cells treated with angiotensin II or phenylephrine
in the absence or presence of antioxidants. The two agents
inhibited enzymatic activity, whereas pre-treatment with N-acetyl-
L-cysteine (NAC) blocked the decrease induced by both com-
pounds (Fig. 6A). We next confirmed that the oxidative
modification directly altered the activity of purified CK in in vitro
conditions: H2O2 reduced the activity of purified human M-CK,
in the absence but not in the presence of catalase (Fig. 6B). Taken
together, these data suggest that the oxidative modification may be
responsible for the loss of M-CK activity in cardiomyocytes
exposed to stimuli relevant to HF. The xanthine oxidase inhibitor
allopurinol, the NADPH-oxidase inhibitor diphenyliodonium
(DPI), and the mitochondrial complex I inhibitor rotenone
completely prevented the inhibition of CK activity induced by
phenylephrine (Fig. 6C). By contrast the complex III inhibitor
antimycin and the complex II inhibitor 4,4,4,-trifluoro-1[2-
thienyl]-1,3-butanediol did not recover the loss of CK activity
(Fig. 6C).
Discussion
Our findings show that oxidative stress-induced protein
modifications are increased in the myocardium of HF patients,
and the proteomic approach made it possible to ascertain that two
proteins mainly underwent carbonylation, ACTC and, to a greater
extent M-CK. Moreover, we found that CK activity was
significantly impaired in the myocardium of HF patients. The
exposure of in vitro cultured cardiomyocytes to stimuli relevant to
the physiopathology of HF led to ROS generation, the source of
which were mainly by xanthine oxidase, NADPH-oxidase, and
mitochondrial complex I. This phenomenon induced cell protein
carbonylation and the oxidation of CK, which subsequently lost its
enzymatic activity. Given the consequences of oxidative modifi-
cation on protein function, we can hypothesise that the oxidised
biomolecules are not only surrogate markers of oxidative stress,
but may also play a role in the development and/or progression of
HF.
We enrolled HF patients with ischemic or idiopathic dilated
cardiomyopathy. The observation that there was no difference
between the two HF groups in terms of cardiac protein carbonyl
Figure 1. ELISA-measured protein carbonyl levels in the
myocardium of 14 HF patients and 13 controls. *p,0.01 vs
controls.
doi:10.1371/journal.pone.0035841.g001
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content suggests that the enhanced oxidative stress occurs
regardless of the etiology of HF. However, as our study population
was small, we may have missed a minor difference. Moreover, we
studied patients with end-stage chronic HF, and so we cannot
exclude the possibility that protein carbonyl content may be
different in the early stages of HF and be related to etiology.
The analysis of protein carbonyls has some advantages over
analysing lipid peroxidation products because the formation of
Figure 2. Representative 2-DE analysis of carbonylated cardiac proteins. (A): representative whole 2-DE gel stained with Coomassie
Colloidal Blue to visualise all of the proteins from controls and patients with HF. (B): representative whole 2-DE gel of proteins from controls and
patients with HF immunostained with the anti-DNP antibody. Expanded views of the ‘‘area of magnification’’ of the differentially carbonylated
proteins from controls and HF patients stained with Coomassie Colloidal Blue (C) or immunostained with the anti-DNP antibody (D). The spot
numbers indicated in the map are the same as those used for MS identification (Table S1).
doi:10.1371/journal.pone.0035841.g002
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protein-bound carbonyl groups seems to be frequent, and
oxidised proteins are formed relatively early and are relatively
stable. It is known that cells degrade oxidised proteins over hours
if not days, whereas lipid peroxidation products are detoxified
within minutes. Interestingly, protein carbonyl groups form early
and are present for longer than other markers of oxidative stress
[23], and the chemical stability of protein carbonyls makes them
suitable targets for laboratory measurements [24]. Many different
physiological and environmental processes can promote the
generation of ROS, including a number of free radicals, various
non-radical oxygen derivatives, and highly reactive lipid- or
carbohydrate-derived carbonyl compounds. Finally, carbonyl
groups are only produced in the presence of severe oxidative
stress, and are considered a sign of both oxidative stress itself and
protein dysfunction [14]. However, carbonyls are not an index of
all oxidative protein modifications, such as the conversion of
tyrosine residues to 3-chlorotyrosine, 3-nitrotyrosine, dityrosine
or methionine oxidation [14], and so the possibility that other
types of modification may occur in patients with HF cannot be
excluded. Nitrotyrosine has so far been found to be mainly
present in a single protein corresponding to SERCA2a in the
failing heart [25].
Oxidative damage often leads to the loss of specific protein
function [16]. The inter-relationships of protein oxidation, protein
dysfunction and diseases are still unclear, but it is known that
oxidative changes in enzymes and structural proteins play a
significant role in the pathophysiology of diseases such as
Alzheimer’s disease [26] and atherosclerosis [27].
One of the main findings of the present study is that M-CK
undergoes carbonylation in the myocardium of HF patients. CK
is a major enzyme involved in energy maintenance and transfer
in muscle and brain cells, and catalyses the reversible transfer of
a phosphate moiety between ATP and creatine. It consists of
hetero- and homodimers of two subunits, B and M, and CK
isoenzymes are specifically distributed in cardiac cells with the
predominant myofibrillar-bound M-isoenzyme, whereas the B-
forms contribute little to overall CK activity [28]. MM-CK has
been found in myofibrils and described as a structural protein of
the M band participating in connections between myosin
filaments inside muscle fibers [29]. This bound MM-CK is
functionally coupled to the myosin ATPase, and can provide
enough energy to sustain maximal force and the normal kinetics
of contraction [30].
It has been recently shown that patients with HF show a
generalized alteration in energy metabolism, particularly the CK
system, with a decrease in total enzyme activity and velocity, and
an altered isoenzyme pattern that could contribute to the
pathogenesis of HF [31]. This was also confirmed by our finding
that CK activity is impaired in the myocardium of HF patients.
Moreover, in patients with dilated cardiomyopathy, the phospho-
creatine (PCr)/ATP ratio, which is governed by CK activity, may
predict both total and cardiovascular mortality [32]. However, the
Figure 3. Intracellular generation of ROS in cardiomyocytes exposed to various compounds. (A) Relative DCF fluorescence of ROS
generation. (B) Percentage increase in ROS generation vs control cells after 5 min. *p,0.01 vs control cells; n = 5. PE, phenylephrine; ISO,
isoprotenerol; NE, norepinephrine; AngII, angiotensin II; ET-1, endothelin-1, TNFa, tumor necrosis factor a.
doi:10.1371/journal.pone.0035841.g003
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precise cellular mechanisms by which altered CK impairs energy
fluxes and contractility are not clearly understood. In addition to
alterations in protein abundance, CK activity may also be affected
by post-translational modifications, including oxidation. A number
of studies have shown that the in vitro exposure of CK to ROS or
derivatives of nitric oxide, such as peroxynitrite, inhibits CK
activity as a result of changes in critical residues within the enzyme
[33]. Our hypothesis that oxidative modifications may be behind
the reduction in CK activity in the failing heart is supported by the
findings presented in this study that the ratio of carbonylated CK
to total CK is higher in the myocardium of HF patients; that pro-
oxidant stimuli induce CK oxidation in in vitro cultured
cardiomyocyte, and concomitantly decrease its enzymatic activity;
and that the antioxidant NAC and inhibitors of ROS prevent the
loss of CK activity.
The enzyme inactivation induced by protein carbonylation may
be due to various mechanisms. The active site of CK isoenzymes
contains an essential cysteine residue and tyrosine residues that
could be targets for the oxidative modifications [34]. The oxidative
inactivation of CK might involve the direct free radical-mediated
oxidation of these aminoacid residues at the CK site to which ATP
binds, a modification that may be due to the reaction of hydrogen
peroxide with small amounts of transition metals that can bind to
histidines near the active site [35]. Alternatively, the interactions of
essential amino acids with the reactive di- or polyaldehyde
compounds generated as a result of oxidative stress in a failing
heart may block ATP binding to CK, and lead to the introduction
of carbonyl groups into CK protein [36]. Oxidative modifications
involving carbonylation and the loss of CK activity have been
previously demonstrated in the brains of patients with Alzheimer’s
disease [37] and in the limb muscles of patients with chronic
obstructive pulmonary disease [38].
Figure 4. Immunofluorescence analysis of carbonylated proteins in cardiomyocytes after treatment with angiotensin II (AngII) or
phenylephrine (PE). The cells were stained with anti-DNP antibody and visualised by means of a secondary antibody conjugated with Alexa Fluor
dye 488. Representative of three independent experiments.
doi:10.1371/journal.pone.0035841.g004
Figure 5. Detection of protein carbonyls after immunoprecip-
itation of M-CK from cell lysate. HL-1 cells were treated with
angiotensin II (AngII) or phenylephrine (PE) for 24 h, and the
immunoprecipitates were immunoblotted with anti-DNP and anti-CK.
Representative of three independent experiments.
doi:10.1371/journal.pone.0035841.g005
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As our data indicate that CK is a target of ROS in the failing
heart, oxidative changes in CK that impair its enzymatic activity
may help to explain the decrease in CK activity and consequent
defects in energy metabolism associated with HF.
Considering that the nitroso/redox balance is an emerging
regulator of cardiovascular homeostasis [39], we have also assessed
the occurrence of S-nitrosylation in the human failing heart.
S-Nitrosylation is a reversible protein modification in which
nitric oxide is covalently bound to a thiol group, leading to the
formation of S-nitrosothiols. The relevance of protein nitrosylation
is currently under debate. Indeed, it plays an important role in a
wide range of NO-mediated cardiovascular effects, including but
not limited to mitochondrial metabolic regulation, intracellular
Ca2+ handling, protein trafficking, and regulation of cellular
defense against apoptosis and oxidative stress. However, depend-
ing on the localization of NO/SNO signaling, the level of protein
S-nitrosylation, and/or interaction with other signaling pathways,
the overall effect of protein S-nityrosylation can be protective or
detrimental. Furthermore, it has been suggested that S-nitrosyla-
tion can protect reactive thiol groups from more irreversible
oxidation [40].
Inactivation of CK activity by S-nitrosylation was observed
primarily in vitro, whereas Decking et al. demonstrated [41] that, in
the intact guinea pig hearts, the NO-induced reduction in cardiac
energy status was associated with an increase in mitochondrial
NADH and is not due to inhibition of CK.
On the other hand, in a relevant HF model, the SHHF rat, the
global S-nitrosylation was decreased in failing hearts compared
with nonfailing hearts, and, specifically, the cardiac RyR2 is
hyponitrosylated due to nitroso-redox imbalance. Xanthine
oxidase inhibition restored global and RyR2 nitrosylation and
reversed the diastolic SR Ca2+ leak, improving Ca2+ handling and
contractility [42].
Our results indicate that the pattern of S-nitrosylated proteins
was similar in the non failing and failing heart confirming the
results by Canton et al [43], and, in particular, CK did not display
a different nitrosylation status in the failing heart.
Thus, we can conclude that in the human failing heart CK
mainly undergoes carbonylation.
However, it is difficult to assess if CK carbonylation mediates
functional and metabolic alteration that lead to HF or is an
epiphenomenon that reflects cardiomyocytes injury.
Figure 6. CK activity in cardiomyocytes. (A) CK activity in cell lysate measured after pretreatment with NAC (N-acetyl-L-cysteine) for 1 h, and
then with angiotensin II (AngII) or phenylephrine (PE) for 4 h in the absence or presence of NAC. (B) Oxidative modification of CK activity in vitro.
Purified human M-CK (30 units/mL) was incubated for 1 h at 25uC with H2O2 (1 mmol/L) in 25 mmol/L Tris-HCl (pH 7.4) in the absence or presence of
100 units/mL of catalase before measurement of CK activity. *p,0.05 vs CK alone. (C) CK activity in cells lysate measured after pretreatment with
different ROS inhibitors for 1 h, and then with phenylephrine (PE) for 4 h. *p,0.05 vs control; #p,0.05 vs PE-treated cells, 1p,0.05 vs AngII-treated
cells (n = 5).
doi:10.1371/journal.pone.0035841.g006
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Although to a lesser extent than CK, oxidation also affects
ACTC, the main component of the thin filament of the sarcomere
in cardiac myocytes.
The number and distribution of cytoskeleton elements are
altered in a sub-population of cardiomyocytes in hypertrophied
[44] and failing myocardium [45], which suggest that myofibrillar
and thin filament changes may contribute to the contractile
deficiencies associated with human myocardial failure. However,
isoform shifts in thin and thick filament proteins are probably not
sufficient by themselves to be considered major factors in
myofilament remodelling. It is likely that post-translational
changes in thin filament proteins play a functional role in some
forms of cardiomyopathy because increased levels of circulating
troponin I suggesting the ongoing proteolitically degradation of
troponin have been observed in patients with severe HF and no
clinical evidence of ischemia [46]. Another important potential
contributor is contractile protein phosphorylation, which can be
altered as a result of changes in kinase and/or phosphatase
activity, and our findings now add protein carbonylation to the list
of post-translational modifications targeting actin in the failing
myocardium.
Given their abundance in mammalian cells, it is likely that actin
filaments are common targets for a variety of ROS and reactive
carbonyl species [47]. A significant increase in the carbonyl
content of b-actin has been found in human brain regions severely
affected by Alzheimer’s disease [48], in macrophages exposed to
hyperoxia [49], and in the skeletal muscles of a diabetes model in
rat [50]. Furthermore, actin carbonylation leading to the
disruption of the actin cytoskeleton and the loss of monolayer
barrier function has been found in human intestinal cells following
exposure to an oxidant insult [51], as well as in the colon mucosa
of patients with Crohn’s disease [52].
Furthermore, oxidised sarcomeric and non-sarcomeric actin
isoforms have been found in association with significantly
depressed post-ischemic contractile function in isolated rat hearts
[53] and, more recently, in human hearts, with an inverse
correlation to LVEF [43]. Recent data have shown that actin
Cys374 may partially act as a scavenger of a,b-unsaturated
aldehydes and other electrophilic lipids containing an unsaturated
carbonyl group because of its accessible surface and the substantial
thiol acidity due to the particular microenvironment surrounding
it [54]. Its reactivity against reactive electrophilic carbonyls and its
relatively high concentration in comparison with other potential
nucleophilic protein targets may explain why oxidised actin was
also found in control hearts [55]. Our and others’ previous
observations [43,47] raise the possibility that actin carbonylation
may be a mechanism by which oxidative stress controls the
organisation of the actin cytoskeleton and regulates the actin
dynamics leading to pathological functional impairments.
In the present study functional protein carbonyl groups were
analyzed with a highly sensitive assay that involved derivatization
with 2,4-dinitrophenylhydrazine (DNPH) to yield a stable 2,4-
dinitrophenylhydrazone-protein (DNP-protein) [14] together with
two-dimensional electrophoresis and immunoblotting which has
been recently reviewed and it is still considered a good approach
for the study of oxidized proteins in proteomics [56]. However,
our study did not identify the exact amino acid sites of carbonyl
modification, which could be necessary for a deeper understanding
of the oxidative mechanisms leading to the protein modification.
Despite the introduction of many different methods [57], none of
them reliably identifies all of the carbonylated amino acid sites,
which are not very abundant on endogenously modified proteins;
this highlights the need to develop even more sensitive methods.
Nevertheless, our data indicate that two cardiac proteins are
targets of ROS in the myocardium of HF patients: ACTC and
principally M-CK, which loses its enzymatic activity and thus
provides a possible explanation of the defective energy metabolism
observed in the failing heart. Our previous findings show that also
the plasma proteins a-1-antitrypsin and fibrinogen are oxidized in
HF patients, and, that their oxidation leads to protein dysfunction;
the first loses its protective inhibitory activity against elastase,
and the second becomes cytotoxic, two events that may contribute
to the endothelial damage associated with heart failure [18].
Overall, these data suggest that altered oxidation pathways
observed in HF can lead to specific post-translational modifica-
tions of relevant proteins and thus contribute to the disease.
Finally, proteomic studies allow a much wider view of oxidative
stress responses than conventional biochemical methods and,
together with dedicated biochemical tools and mass spectrometry-
based quantitative techniques, will make it possible to study
changes in the expression and oxidative modifications of
unpredictable proteins.
Limits of the Study
Few study limitations should be acknowledged. First, our study
involved a small number of cases and studies of larger population
are certainly needed. Secondly, as we used myocardium obtained
from patients undergoing cardiac transplantation, our results apply
to subjects with real end-stage heart failure. No data are available
concerning patients with less severe heart failure, and so the
progression of myocardial protein oxidation during the natural
evolution of heart failure is unknown.
Moreover although the protein oxidation in the myocardium of
patients with end-stage heart failure seems to be qualitatively and
quantitatively important, it is not known whether it is deleterious
or not, nor whether it can be modulated by drugs: two aspects that
need further investigation in larger patient series. It is well known
that although extensive studies have linked free-radical injury to
HF, there is currently no antioxidant-based therapy that is being
used in patients with this disease. We agree with the Authors of a
recent review [58] who assess that to develop effective and safe
therapeutic strategies that target oxidative stress, we must first
understand the ROS-generating molecular pathways that may be
involved in the pathogenesis of HF. It is important to emphasize
that in the heart there are complex and dynamic molecular
pathways involved in ROS formation. Therefore the inability to
elucidate the beneficial effects of antioxidant strategies in humans
may be attributed to the fact that only specific ROS-generating
pathways may be modifiable or worth modulating. Furthermore,
one of the major limitations in administrating antioxidants to
prevent ROS generation in myocardial tissue is the difficulty to
achieving significant local concentrations of the antioxidants. If,
for example, mitochondria are involved in the ROS generation,
antioxidants specifically targeted to this local source are needed.
Our study shows that xanthine oxidase, NADPH-oxidase, and
mitochondrial complex I prevented the loss of CK activity induced
by phenylephrine. Therefore, an in vivo antioxidant treatment
should take into consideration these specific pathways. Indeed,
pharmacological strategies are currently examining the role of
xanthine oxidase inhibitors, such as allopurinol and oxypurinol, in
targeting oxidative stress in HF [58]. Studies in animal models of
HF have demonstrated that allopurinol reverses left ventricular
remodeling, improves LVEF, and reduces endothelial dysfunction
in HF. However, clinical studies have yielded inconsistent results
probably because it is important to target a specific population of
patients with HF; for instance, patients with moderate-to severe
HF that had elevated serum uric acid levels are most likely to
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benefit from allopurinol treatment, the cornerstone of the clinical
management of gout and conditions associated with hyperurice-
mia for several decades [59].
Finally, like most proteomic studies of human samples, our
study largely provides a descriptive list of differentially expressed
proteins and, although they have the potential value of identifying
biomarkers of human disease for clinical use, such studies have not
yet provided the substantial mechanistic insights [60] needed to
improve our understanding of the physiopathology of the disease.
Only when the findings of discovery proteomic studies are used to
shed light on the mechanisms of heart disease will they begin to
show their full potential, and may allow the development of new
therapeutic strategies for cardiac diseases.
In conclusion, our findings show that protein oxidation is
increased in the myocardium during HF, but it is still not clear if
oxidative stress plays a causal role in heart failure, is an
epiphenomenon unrelated to its pathogenesis, or even a conse-
quence of the disease.
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Figure S1 Detection of S-nitrosylated CK in myocardium from
HF patients and controls. (A). Nitrosylated proteins have been
biotinylated and subjected to immunoprecipitation of creatine
kinase (CK). Immunoblots were performed with anti-CK, to
confirm the immunoprecipitation, and with an anti-biotin
antibody, to identify S-nitrosylated CK. (B). The amount of S-
nitrosylated CK was given by the ratio between densitometric
values of the S-nitrosylated band and those of the CK band.
Values are mean6SD. (C). Representative 1-DE image of total
nitrosylated proteins in myocardium of controls and HF patients.
Nitrosylated proteins have been biotinylated and equal amount of
proteins have been subjected to immunoblotting with a biotin
detection reagent.
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